Education
About Us
Working with TipRanks
Follow Us
KALA BIO (KALA)
NASDAQ:KALA
KALA Stock Chart & Stats
$0.62
-$0.34(-4.42%)
At close: 4:00 PM EST
$0.62
-$0.34(-4.42%)
Day’s Range― - ―
52-Week Range$0.34 - $20.60
Previous CloseN/A
Volume15.45K
Average Volume (3M)1.94M
Market Cap
$319.60M
Enterprise Value$17.52M
Total Cash (Recent Filing)$21.10M
Total Debt (Recent Filing)$31.05M
Price to Earnings (P/E)―
Beta1.55
Next Earnings
Mar 26, 2026EPS Estimate
-0.32Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.01
Shares Outstanding911,330,200
10 Day Avg. Volume624,022
30 Day Avg. Volume1,940,241
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)3.11
Price to Sales (P/S)0.00
P/FCF Ratio-1.29
Enterprise Value/Market Cap0.05
Enterprise Value/Revenue69.00
Enterprise Value/Gross Profit-2.19K
Enterprise Value/Ebitda-0.57
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.53
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt Overhang EliminatedSettling the ~$10.6M Oxford liability materially reduces near-term creditor pressure and covenant/default risk. This improves financial flexibility and cash flow optionality for financing R&D and clinical programs, making capital structure management and strategic partnerships easier over the medium term.
Demonstrated Access To Equity CapitalSuccessful direct and preferred offerings plus an ATM program show repeated investor willingness to fund the company. Sustained access to equity capital is a structural enabler for a clinical-stage biotech to progress trials, fund operations, and pursue partnerships without revenue, reducing immediate solvency risk.
Leadership And Strategic Financing AlignmentA new CEO tied to financing transactions signals active governance and strategic focus on stabilizing operations. Leadership that secures committed funding and coordinates settlements can improve execution of clinical and capital plans, impacting long-term ability to advance assets and negotiate partnerships.
Bears Say
Near-zero Recurring Revenue And Heavy Cash BurnWith essentially no product revenue and persistent ~-$32M TTM operating cash burn, the company lacks an internal cash-generating engine. This structural dependence on external financing increases dilution risk and constrains long-term R&D planning if capital markets tighten or investor appetite wanes.
Negative Equity And Elevated LeverageNegative shareholders' equity and material outstanding debt weaken the balance sheet, limiting borrowing capacity and increasing refinancing risk. A strained capital structure reduces strategic optionality, raises creditor negotiation leverage, and increases the likelihood that future funding will be dilutive or costly.
Nasdaq Listing Compliance RiskA Nasdaq deficiency notice creates a persistent governance and market-access risk: potential delisting or remedy actions (reverse split) can reduce liquidity, deter institutional investors, and complicate equity financing or partnering, making long-term capital access and shareholder stability more uncertain.
KALA BIO News
KALA FAQ
What was KALA BIO’s price range in the past 12 months?
KALA BIO lowest stock price was $0.34 and its highest was $20.60 in the past 12 months.
What is KALA BIO’s market cap?
KALA BIO’s market cap is $319.60M.
When is KALA BIO’s upcoming earnings report date?
KALA BIO’s upcoming earnings report date is Mar 26, 2026 which is in 21 days.
How were KALA BIO’s earnings last quarter?
KALA BIO released its earnings results on Nov 17, 2025. The company reported -$1.01 earnings per share for the quarter, the consensus estimate of -$1.01 by $0.
Is KALA BIO overvalued?
According to Wall Street analysts KALA BIO’s price is currently Overvalued.
Does KALA BIO pay dividends?
KALA BIO does not currently pay dividends.
What is KALA BIO’s EPS estimate?
KALA BIO’s EPS estimate is -0.32.
How many shares outstanding does KALA BIO have?
KALA BIO has 911,330,200 shares outstanding.
What happened to KALA BIO’s price movement after its last earnings report?
KALA BIO reported an EPS of -$1.01 in its last earnings report, expectations of -$1.01. Following the earnings report the stock price went down -0.992%.
Which hedge fund is a major shareholder of KALA BIO?
Currently, no hedge funds are holding shares in KALA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
KALA BIO
Kala Bio, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of therapeutics using proprietary nanoparticle-based mucus penetrating particles with an initial focus on the treatment of eye diseases. The company was founded by Justin Hanes, Robert S. Langer and Colin R. Gardner in 2009 and is headquartered in Arlington, MA.
Technical Analysis
Ownership Overview
2.65% Insiders
0.85% Mutual Funds
7.88% Other Institutional Investors
88.39% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---